This document contains: The systematic reviews and GRADE assessments used at the Index-TB Guideline Panel in July 2015; The Evidence to Decision tables that record the Panel’s assessment and recommendations from
this meeting
Schizophr Bull. 2014 Jan;40(1):192-213. doi: 10.1093/schbul/sbs150. Epub 2012 Dec 17.
This Review summarizes many of the persistent biological alterations associated with childhood maltreatment including changes in neuroendocrine and neurotransmitter systems and pro-inflammatory cytokines in addition to specific alterations in brain areas associated with mood regulation. Finally, I d...iscuss several candidate gene polymorphisms that interact with childhood maltreatment to modulate vulnerability to major depression and PTSD and epigenetic mechanisms thought to transduce environmental stressors into disease vulnerability.
Neuron Review, vol. 89, March 2, 2016 pp.892-909
more
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
Q 7: For adults and children with convulsive epilepsy, which standard antiepileptic drugs (phenobarbital, phenytoin, carbamazepine, valproic acid) when compared to placebo/a comparator produce benefits/harm in the specified outcomes?
[Updated 2015]
Scoping Question: In adults with acute convulsive seizures in first-level care or in the community (when no IV access is available), which antiepileptic medications produce benefits and/or harm when compared to comparator?
SCOPING QUESTION: For adults and children with medication-resistant convulsive epilepsy, which anti-epileptic medications produce benefits and/or harm in the specified outcomes when compared to a placebo or a comparator?
Anxiety disorders
Chapter F.2
Q 12: In children and adolescents with anxiety disorders, what is the effectiveness and safety, considering system issues in low- and middle-income countries, of using pharmacological interventions in non-specialist settings?
Q10: Are antidepressants (Tricyclic antidepressants (TCA), Selective serotonin reuptake inhibitors (SSRIs)) effective and safe in children 6-12 years of age with depressive episode/disorder?
Dialogues Clin Neurosci. 2017 Jun; 19(2): 93–107.
Q8.SCOPING QUESTION: In adults and older adolescents with depressive disorder, what is the comparative effectiveness of different formats of psychological treatments?
Q6: Is advice on physical activity better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder with inactive lifestyles
Q14. SCOPING QUESTION: In adults with psychotic disorders (including schizophrenia), what is the comparative effectiveness and safety of second-generation antipsychotic medications?
Accessed: 08.10.2019
Based on the National Guidelines for the Management of Tuberculosis in Children 2013, Department of Health, South Africa.
PLOS ONE | https://doi.org/10.1371/journal.pone.0196239 April 23, 2018